Latest news with #PanaceaBiotec
Business Standard
03-06-2025
- Health
- Business Standard
Panacea Biotec announces inclusion of EmulsiPan into prestigious CEPI Adjuvant Library
Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects. EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8C and maintains stability for over 2-years under recommended conditions. On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.
Business Upturn
03-06-2025
- Health
- Business Upturn
Panacea Biotec's EmulsiPan listed in CEPI Adjuvant Library to support vaccine development
Panacea Biotec Limited has announced the inclusion of its adjuvant, EmulsiPan, in the Coalition for Epidemic Preparedness Innovations (CEPI) Library of adjuvants. This listing aims to support researchers and developers working on vaccines and biotherapeutics. EmulsiPan is an oil-in-water emulsion adjuvant created through the nano-emulsification of squalene, surfactants, and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in plants and humans. EmulsiPan is supplied as a ready-to-use sterile emulsion in 10 mL USP Type I glass vials, intended for research purposes. It is stable for over two years when stored between 2-8°C. The global market for adjuvants is projected to exceed $4.8 billion by 2028, driven by applications in vaccines and biological therapies, including oncology. Oil-in-water emulsion adjuvants, such as EmulsiPan, are commonly used in commercial vaccines, including influenza vaccines. EmulsiPan's availability without licensing fees provides an accessible option for vaccine developers. EmulsiPan has been used in various preclinical studies and collaborative research projects. Notably, it was applied in non-human primate challenge studies for Sarbecoronavirus vaccine candidates at the California Institute of Technology (Caltech) and in Betacoronavirus vaccine development programs in partnership with BRIC-Translational Health Science and Technology Institute (THSTI), funded by CEPI. These studies demonstrate its adaptability and effectiveness in vaccine research. Developed in 2009 and first commercialized as part of Panacea Biotec's H1N1 vaccine, PandyFlu, EmulsiPan has since become a platform adjuvant for multiple vaccine candidates. Panacea Biotec established a cGMP manufacturing facility for EmulsiPan, ensuring consistent quality and regulatory compliance. The inclusion of EmulsiPan in the CEPI Adjuvant Library confirms it has undergone scientific evaluation and meets standards necessary to support human vaccine development. This listing is expected to increase access for researchers and companies interested in using EmulsiPan for commercial or research applications. By offering a stable, ready-to-use formulation and removing licensing fees, Panacea Biotec aims to facilitate equitable access to vaccine adjuvants and contribute to global preparedness for future epidemics and pandemics. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
24-04-2025
- Business
- Business Standard
Panacea Biotec shares locked in 5% upper circuit; here's what to know
Shares of Panacea Biotec surged to hit a 5 per cent circuit on Thursday's session after it received an additional order from the UNICEF for the supply of 40 million doses of its bivalent oral polio vaccine worth $5.20 million (₹44 crore). The pharmaceutical company's stock rose as much as 5 per cent during the day to hit an upper circuit of ₹538.55 per share. The stock trades near its all-time high of ₹549 per share, which it hit on April 21 this year. The company's shares are up 3 per cent this week and have recovered over 85 per cent from their lows of ₹290, which it hit in late February. The stock has risen 28 per cent this year, compared to a 2.6 per cent advance in the benchmark Nifty50. The company has a total market capitalisation of ₹3,300.8 crore, according to BSE data. In an exchange filing on Wednesday, it said that the company received an additional award from United Nations Children's Fund (UNICEF) for the supply of 40 million doses of its bivalent oral polio vaccine, valued at approximately US$5.20 million (around Rs 44 crore), for delivery in the third quarter of calendar year 2025. This comes after the company has already received orders from UNICEF for the supply of 115 million doses of its bivalent oral polio vaccine worth $14.95 million (~Rs.127 Crore) in this calendar year. About Panacea Biotec Panacea Biotec is an Indian biotechnology and pharmaceutical company specialising in the research, development, and manufacturing of vaccines, biologics, and pharmaceutical formulations. Established in 1984, the company is known for its innovative healthcare solutions, particularly in the areas of immunisation and life-saving therapeutics. Panacea Biotec has developed vaccines for diseases including polio, tetanus, and hepatitis, and collaborates with global organisations such as the WHO, UNICEF, and Gavi to distribute its vaccines worldwide. In addition to vaccines, its pharmaceutical portfolio covers therapies for oncology, organ transplantation, diabetes, and cardiovascular conditions. With a strong focus on research and cutting-edge technology, Panacea Biotec aims to address critical healthcare needs globally.
Business Upturn
24-04-2025
- Business
- Business Upturn
Panacea Biotec shares hit 5% upper circuit after additional UNICEF vaccine order worth Rs 44 crore
By Aman Shukla Published on April 24, 2025, 10:46 IST Panacea Biotec shares surged 5% to hit the upper circuit on April 24, 2025, following the announcement of an additional order from UNICEF for the supply of its bivalent oral polio vaccine (bOPV). This new order supplements an earlier contract communicated on December 24, 2024. At that time, UNICEF had awarded Panacea Biotec a contract for 115 million doses, valued at approximately USD 14.95 million (around Rs.127 crore), scheduled for delivery during the 2025 calendar year. Under the latest development, Panacea Biotec has secured an additional contract for 40 million doses of bOPV, equivalent to 2 million vials. The value of this new order is approximately USD 5.20 million (around Rs.44 crore). The supply is expected to be executed in the third quarter of 2025. The order has been placed under the existing long-term arrangement between Panacea Biotec and UNICEF. This arrangement will be updated to reflect the latest award. Panacea Biotec shares opened at ₹524.00 today, hitting a high of ₹538.55 and dipping to a low of ₹519.10. The stock is trading close to its 52-week high of ₹549.05, a significant rise from its 52-week low of ₹112.35. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
23-04-2025
- Business
- Business Upturn
Panacea Biotec secures additional $5.2 million polio vaccine order from UNICEF
By Aman Shukla Published on April 23, 2025, 15:34 IST Panacea Biotec has announced an additional order from UNICEF for the supply of its bivalent oral polio vaccine (bOPV). This follows a previous communication dated December 24, 2024, regarding an initial award for 115 million doses valued at approximately USD 14.95 million (around Rs.127 crore) to be supplied during the calendar year 2025. The company has now secured an additional contract from UNICEF. This new award involves the supply of 40 million doses (equivalent to 2 million vials) of bOPV, valued at around USD 5.20 million (approximately Rs.44 crore). The supply is scheduled for execution in the third quarter of calendar year 2025. The order has been placed under the existing long-term arrangement between Panacea Biotec and UNICEF, which will be updated accordingly. UNICEF is expected to publish the details of the award, including the supplier's name, vaccine details, duration, total value, and awarded prices on its website. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
